Payment overview · 2025
General Payments
$469.61
28 reported records · 8 companies
Healthcare provider profile · identity verified
Andrew Clark Coleman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PARIS, TN · NPI 1770565459
Verified facts
What the public records show
CMS Open Payments records show Andrew Clark Coleman, M.D. received $469.61 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 738 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.34 | 35.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.33 | 29.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.27 | 10.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.86 | 7.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.36 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.09 | 4.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.86 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.50 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $469.61 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $128.43 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $127.41 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $91.99 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.42 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 738 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 245 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
738 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1496 | 212 |
| Furosemide | Furosemide | 1148 | 114 |
| Omeprazole | Omeprazole | 1130 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 987 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 943 | 120 |
| Sertraline Hcl | Sertraline Hcl | 933 | 53 |
| Potassium Chloride | Potassium Chloride | 846 | 92 |
| Trazodone Hcl | Trazodone Hcl | 838 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 807 | 112 |
| Eliquis | Apixaban | 738 | 72 |
| Donepezil Hcl | Donepezil Hcl | 722 | 38 |
| Losartan Potassium | Losartan Potassium | 658 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 629 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 626 | 48 |
| Lisinopril | Lisinopril | 600 | 74 |
| Divalproex Sodium | Divalproex Sodium | 556 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 554 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 496 | 57 |
| Mirtazapine | Mirtazapine | 495 | 39 |
| Famotidine | Famotidine | 467 | 35 |
| Memantine Hcl | Memantine Hcl | 459 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 439 | 60 |
| Spironolactone | Spironolactone | 421 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 415 | 58 |
| Paroxetine Hcl | Paroxetine Hcl | 398 | 20 |
| Simvastatin | Simvastatin | 394 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 391 | 23 |
| Meloxicam | Meloxicam | 386 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 376 | 30 |
| Metformin Hcl | Metformin Hcl | 371 | 78 |
| Gabapentin | Gabapentin | 362 | 69 |
| Ropinirole Hcl | Ropinirole Hcl | 357 | 20 |
| Carvedilol | Carvedilol | 348 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 325 | 65 |
| Alprazolam | Alprazolam | 323 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 319 | 41 |
| Buspirone Hcl | Buspirone Hcl | 298 | 24 |
| Levetiracetam | Levetiracetam | 283 | 21 |
| Risperidone | Risperidone | 282 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 268 | 32 |
| Lamotrigine | Lamotrigine | 268 | 15 |
| Glimepiride | Glimepiride | 264 | 43 |
| Prednisone | Prednisone | 257 | 65 |
| Allopurinol | Allopurinol | 253 | 42 |
| Jardiance | Empagliflozin | 245 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 244 | 15 |
| Atenolol | Atenolol | 235 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 60 |
| Hydralazine Hcl | Hydralazine Hcl | 228 | 14 |
| Montelukast Sodium | Montelukast Sodium | 215 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 214 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 30 |
| Tramadol Hcl | Tramadol Hcl | 202 | 48 |
| Amiodarone Hcl | Amiodarone Hcl | 197 | 15 |
| Digoxin | Digoxin | 194 | suppressed |
| Olanzapine | Olanzapine | 194 | 14 |
| Oxcarbazepine | Oxcarbazepine | 193 | suppressed |
| Ozempic | Semaglutide | 188 | 28 |
| Diltiazem 24hr Er | Diltiazem Hcl | 187 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 183 | 22 |
| Celecoxib | Celecoxib | 179 | 37 |
| Metformin Hcl Er | Metformin Hcl | 177 | 26 |
| Benazepril Hcl | Benazepril Hcl | 176 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 23 |
| Sucralfate | Sucralfate | 175 | 11 |
| Midodrine Hcl | Midodrine Hcl | 170 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 161 | 37 |
| Myrbetriq | Mirabegron | 157 | suppressed |
| Xarelto | Rivaroxaban | 149 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 148 | 17 |
| Clonazepam | Clonazepam | 144 | 16 |
| Estradiol | Estradiol | 141 | 17 |
| Levofloxacin | Levofloxacin | 141 | 101 |
| Valsartan | Valsartan | 137 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 130 | 87 |
| Methocarbamol | Methocarbamol | 129 | 12 |
| Aripiprazole | Aripiprazole | 127 | 11 |
| Januvia | Sitagliptin Phosphate | 127 | 15 |
| Rivastigmine | Rivastigmine | 121 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 118 | suppressed |
| Lansoprazole | Lansoprazole | 117 | suppressed |
| Ezetimibe | Ezetimibe | 114 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 112 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 110 | 29 |
| Finasteride | Finasteride | 109 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 38 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 103 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 102 | suppressed |
| Torsemide | Torsemide | 102 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 19 |
| Cefdinir | Cefdinir | 98 | 68 |
| Chlorthalidone | Chlorthalidone | 96 | 20 |
| Labetalol Hcl | Labetalol Hcl | 95 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 27 |
| Paliperidone Er | Paliperidone | 88 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 86 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 86 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 16 |
| Alendronate Sodium | Alendronate Sodium | 85 | 27 |
| Clonidine Hcl | Clonidine Hcl | 85 | 15 |
| Lovastatin | Lovastatin | 84 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 80 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 21 |
| Naproxen | Naproxen | 76 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 75 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 16 |
| Galantamine Er | Galantamine Hbr | 73 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 68 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 49 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | suppressed |
| Linzess | Linaclotide | 61 | 13 |
| Bupropion Xl | Bupropion Hcl | 60 | 17 |
| Promethazine Hcl | Promethazine Hcl | 60 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 59 | 15 |
| Warfarin Sodium | Warfarin Sodium | 59 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 42 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 57 | suppressed |
| Haloperidol | Haloperidol | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 56 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 17 |
| Meclizine Hcl | Meclizine Hcl | 51 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | suppressed |
| Lactulose | Lactulose | 50 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 48 | suppressed |
| Nystatin | Nystatin | 48 | 23 |
| Amoxicillin | Amoxicillin | 47 | 24 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Famciclovir | Famciclovir | 47 | suppressed |
| Lorazepam | Lorazepam | 47 | suppressed |
| Novolog | Insulin Aspart | 47 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Baclofen | Baclofen | 46 | 14 |
| Galantamine Hbr | Galantamine Hbr | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 46 | suppressed |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 31 |
| Carbamazepine Er | Carbamazepine | 44 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Diltiazem 12hr Er | Diltiazem Hcl | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Lidocaine | Lidocaine | 44 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 44 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 43 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 43 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 43 | suppressed |
| Riluzole | Riluzole | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Ursodiol | Ursodiol | 43 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 42 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 42 | suppressed |
| Trimethoprim | Trimethoprim | 42 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Cilostazol | Cilostazol | 40 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 25 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 38 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 19 |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Ibuprofen | Ibuprofen | 35 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Phenytoin | Phenytoin | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 25 |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Lidocaine Hcl | Lidocaine Hcl | 27 | 17 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 12 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Insulin Aspart | Insulin Aspart | 20 | suppressed |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xolair | Omalizumab | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $469.61 · 28 records | Novo Nordisk Inc | CAPLYTA, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error